+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 22 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a combination of three drugs inavolisib, ribociclib, and fulvestrant, compared to a placebo combined with ribociclib and fulvestrant. This study focuses on participants with advanced breast cancer that is resistant to hormone therapy, specifically those with hormone receptor-positive, HER2-negative breast cancer. The trial is a Phase II, randomized, double-blind study sponsored by Hoffmann-La Roche. Participants are randomly assigned to receive either the triple combination of inavolisib, ribociclib, and fulvestrant, or a placebo with ribociclib and fulvestrant. All medications will be given according to a schedule detailed in the study protocol. The study aims to observe the effects of these treatments over a period of up to approximately two years. During the study, participants will undergo assessments to measure confirmed objective response, progression-free survival, overall survival, and duration of response. Researchers will also monitor clinical benefit, adverse events, and the impact of treatment side effects on daily life using patient-reported questionnaires. Safety and treatment tolerability will be closely observed, with data collected throughout the study duration of up to two years.

Age: 18Years +All GendersPhase 2
59 locations
C

Actively Recruiting

Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.

Age: 18Years +All GendersPhase 3
163 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
C

Actively Recruiting

This trial is designed to evaluate the safety, tolerability, and effectiveness of the combination of nemtabrutinib plus venetoclax compared to venetoclax plus rituximab in adults with relapsed or refractory chronic lymphocytic leukemiasmall lymphocytic lymphoma RR CLLSLL. The study aims to confirm the dose of nemtabrutinib and assess progression-free survival as the primary outcome, using established criteria and independent review. Participants are assigned to one of two treatment groups. One group receives daily oral nemtabrutinib starting on the first day of cycle 1 and venetoclax starting on the first day of cycle 2, continuing up to two years or until disease progression or discontinuation. The other group receives daily oral venetoclax starting on cycle 1 day 1, plus intravenous rituximab infusion for six cycles. Each treatment cycle lasts four weeks. During the study, participants undergo regular monitoring for dose-limiting toxicities, adverse events, and treatment discontinuations. Assessments include progression-free survival, minimal residual disease in bone marrow, overall survival, response rates, and duration of response. The study duration spans several years, with safety and efficacy monitored throughout and follow-up extending beyond treatment completion to gather comprehensive data on participant outcomes.

Age: 18Years +All GendersPhase 3
99 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
G

Actively Recruiting

Researchers are studying the efficacy and safety of rilvegostomig combined with gemcitabine plus cisplatin compared to durvalumab combined with the same chemotherapy as first-line treatment for patients with advanced biliary tract cancer BTC. This Phase III, randomized, open-label study aims to evaluate these treatments in patients with unresectable locally advanced or metastatic BTC, including intra-hepatic or extra-hepatic cholangiocarcinoma and gallbladder carcinoma. Participants receive either rilvegostomig or durvalumab intravenously, both alongside gemcitabine and cisplatin chemotherapy. Durvalumab is given at 1500 mg IV every 3 weeks for up to 8 cycles, then every 4 weeks. Rilvegostomig is administered IV every 3 weeks. The chemotherapy regimen consists of gemcitabine 1000 mgm2 plus cisplatin 25 mgm2 on Day 1 and Day 8 of each 21-day cycle. Treatment continues according to the study protocol with close monitoring. During the study, participants undergo assessments including tumor measurements by CT or MRI using RECIST 1.1 criteria, evaluation of PD-L1 status, and performance status checks. Researchers also monitor overall survival and progression-free survival for up to approximately four years, as well as safety, tolerability, pharmacokinetics, and patient-reported symptoms and quality of life. Follow-up continues up to 12 weeks after disease progression for additional evaluations.

Age: 18Years +All GendersPhase 3
183 locations
R

Actively Recruiting

Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.

Age: 18Years +All GendersPhase 2
456 locations
C

Actively Recruiting

Researchers are studying the molecular features present in people receiving care within a large community-based healthcare system to better understand cancer biology. The study focuses on identifying the genetic causes behind premalignant and malignant conditions across various cancer stages and types. This observational research aims to advance cancer research through comprehensive genomic profiling and deep clinical data analysis. Participants will undergo extensive molecular testing including somatic tumor testing from tissue or blood samples using next-generation sequencing. Some samples may also be analyzed with whole exome or whole transcriptome sequencing for research purposes. Pharmacogenomic testing will be performed to study how individual genetics affect medication responses. Participants may optionally provide microbiome samples. Electronic health records, both past and future, will be collected and linked to genomic data, with optional storage of biological samples in a biobank for future research. During the study, data from genomic tests and health records will be gathered to support cancer research and biomarker discovery. Researchers will track participation rates in molecular profiling, genetic testing referrals, and clinical trial referrals over five years. Additional outcomes include therapy changes based on profiling results and microbiome analysis participation. The study will continue collecting data for up to five years, with a focus on long-term clinical annotation and research contributions.

Age: 18Years +All Genders
6 locations

1-10 of 22

1